GO
Loading...

Enter multiple symbols separated by commas

Stocks Celgene Corp

More

  • July 14- Celgene Corp said on Tuesday it would buy Receptos Inc for $7.2 billion in a move that will give the U.S. biotechnology company a potential multibillion-dollar drug in late stage development for inflammatory bowel disease and multiple sclerosis. The Receptos move comes just two weeks after Celgene said it would invest $1 billion in Juno Therapeutics...

  • UPDATE 1-Celgene to buy Receptos for $7.2 bln Tuesday, 14 Jul 2015 | 5:41 PM ET

    July 14- Celgene Corp said on Tuesday it would buy Receptos Inc for $7.2 billion in a move that will give the U.S. biotechnology company a potential blockbuster drug in late stage development for inflammatory bowel disease and multiple sclerosis. The move comes just two weeks after Celgene said it would invest $1 billion in Juno Therapeutics to gain access to...

  • After-hours buzz: Yum, CSX, Celgene & more Tuesday, 14 Jul 2015 | 5:36 PM ET
    Traders work the floor of the New York Stock Exchange.

    Check out the companies making headlines after the bell Tuesday: Yum, CSX, Celgene & more.

  • Celgene to buy Receptos for $7.2 bln Tuesday, 14 Jul 2015 | 5:15 PM ET

    July 14- Celgene Corp said it agreed to buy Receptos Inc for about $7.2 billion to expand its pipeline with Receptos' immune-inflammatory bowel drug, Ozanimod. Celgene will pay $232 in cash for every Receptos share, representing a 12 percent premium to the company's closing price on Tuesday. Ozanimod is in late-stage trials for inflammatory bowel disease and...

  • Receptos stock soars on deal with Celgene Tuesday, 14 Jul 2015 | 5:02 PM ET
    Abraxane by Celgene

    Celgene announced Tuesday that it will acquire Receptos for $232 per share in cash for a total of about $7.2 billion.

  • AstraZeneca divests gastrointestinal drug for $215 mln Thursday, 9 Jul 2015 | 3:07 AM ET

    LONDON, July 9- AstraZeneca struck a further "externalisation" deal on Thursday to help fill its short-term revenue gap by divesting its gastrointestinal drug Entocort for $215 million. The transaction is expected to complete in the second half of 2015 and AstraZeneca said it would reinforce its strategic focus on selected therapy areas, such as cancer,...

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed higher on Tuesday in a slight recovery from the worst trading day of the year, as investors remained on edge amid the imminent Greece repayment deadline to the IMF.

  • Demonstrators are shown during a rally in Athens, Greece, June 29, 2015.

    Managers discuss Greece, volatility and how to play it

  • June 30- U.S. stocks shed some of their early gains on Tuesday as nervous investors wondered whether last-minute talks would produce a bailout deal that would keep Greece in the euro. German Chancellor Angela Merkel told lawmakers she did not expect any new developments, appearing to dash hopes of a deal before Greece defaults on a 1.6 billion euro payment to the...

  • June 30- Wall Street was set to open higher on Tuesday, a day after the Dow and the S&P 500 registered their worst session since October, as investors hoped Greece would strike a last-minute deal to avoid an exit from the euro zone. Greece is hours away from defaulting on a 1.6 billion euro repayment to the International Monetary Fund. U.S. corporations have limited...

  • Early movers: PNR, CAG, GE, FIT, JUNO, GM & more Tuesday, 30 Jun 2015 | 7:57 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Juno, Celgene's $1B cancer-fighting deal: CEO Tuesday, 30 Jun 2015 | 7:15 AM ET
    Juno, Celgene's $1B cancer-fighting deal: CEO

    Hans Bishop, Juno Therapeutics CEO, discusses the company's strategic collaboration with Celgene to develop advance immunotherapies for patients with cancer and autoimmune diseases.

  • Celgene places $1B bet on Juno Therapeutics Tuesday, 30 Jun 2015 | 1:45 AM ET

    Biotech giant Celgene has invested $1 billion in Juno Therapeutics in a move to that backs experimental cancer treatments, the FT reports.

  • Your first trade for Tuesday Monday, 29 Jun 2015 | 6:19 PM ET
    Fast Money Final Trade:  COST, NXPI, RNF & SAVE

    The "Fast Money" traders give their final trades of the day.

  • After-hours buzz: Juno, Apollo Education & more Monday, 29 Jun 2015 | 5:35 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Check out the companies making headlines after the bell Monday: Juno, Apollo Education & more.

  • June 29- Celgene Corp said it would invest about $1 billion in Juno Therapeutics Inc to partner in the development and marketing of immunotherapies for the treatment of cancer and autoimmune diseases. Celgene will pay Juno about $150 million upfront and buy about 10 percent of Juno's shares at $93 each, almost double of Juno's closing price on Monday.

  • June 29- Celgene Corp and Juno Therapeutics Inc said they signed a deal to develop and commercialize immunotherapies for the treatment of cancer and autoimmune diseases. Juno will receive about $150 million upfront, and will sell 9.1 million shares of its common stock at $93 each to Celgene, the companies said on Monday. Shares of Juno were up 61 percent in...

  • June 29- Celgene Corp and Juno Therapeutics Inc said they signed a deal to develop and commercialize immunotherapies for the treatment of cancer and autoimmune diseases. Juno will receive about $150 million upfront, and will sell 9.1 million shares of its common stock at $93 each to Celgene, the companies said on Monday. Shares of Juno were up 61 percent in...

  • Portfolio Playbook: Buy the chips Thursday, 18 Jun 2015 | 3:23 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Portfolio Playbook: Buy the chips

  • Lightning Round: Huge deals ahead for this group Wednesday, 17 Jun 2015 | 7:59 PM ET
    Mad Money Lightning Round

    Jim Cramer sees that this group is ready for some major deals, as he gives his take on caller favorite stocks.